![Louisa Jordison](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Louisa Jordison
Director of Finance/CFO at Sygnature Discovery Ltd.
Profile
Louisa Jordison currently works at Sygnature Discovery Ltd., as Chief Financial Officer & Director and SB Drug Discovery Ltd., as Director from 2022.
Louisa Jordison active positions
Companies | Position | Start |
---|---|---|
Sygnature Discovery Ltd.
![]() Sygnature Discovery Ltd. Pharmaceuticals: MajorHealth Technology Sygnature Discovery Ltd. engages in drug discovery activities. It specializes in target validation, hit identification, hit to lead, lead optimization, integrated drug discovery, and fragment based drug discovery. The company was founded by Simon Christopher Hirst in 2004 and is headquartered in Nottingham, United Kingdom. | Director of Finance/CFO | 2020-12-31 |
SB Drug Discovery Ltd.
![]() SB Drug Discovery Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sygnature Discovery Ltd., SB Drug Discovery Ltd. is a British company that specializes in ion channel services. The company is based in Glasgow, UK. The company offers a portfolio of electrophysiology assays and customized cell line development capabilities to aid in ion channel drug discovery. The company's services include ion channel screening, receptor and enzyme studies, and custom cell line generation expertise. The company also provides a comprehensive panel of sodium (Nav) channel cell lines and assays, as well as HTS and selectivity profiling services to advance hit-to-lead campaigns. The company was founded in 2002. SB Drug Discovery was acquired by Sygnature Discovery Ltd. on January 17, 2023. | Director/Board Member | 2022-12-15 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Sygnature Discovery Ltd.
![]() Sygnature Discovery Ltd. Pharmaceuticals: MajorHealth Technology Sygnature Discovery Ltd. engages in drug discovery activities. It specializes in target validation, hit identification, hit to lead, lead optimization, integrated drug discovery, and fragment based drug discovery. The company was founded by Simon Christopher Hirst in 2004 and is headquartered in Nottingham, United Kingdom. | Health Technology |
SB Drug Discovery Ltd.
![]() SB Drug Discovery Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sygnature Discovery Ltd., SB Drug Discovery Ltd. is a British company that specializes in ion channel services. The company is based in Glasgow, UK. The company offers a portfolio of electrophysiology assays and customized cell line development capabilities to aid in ion channel drug discovery. The company's services include ion channel screening, receptor and enzyme studies, and custom cell line generation expertise. The company also provides a comprehensive panel of sodium (Nav) channel cell lines and assays, as well as HTS and selectivity profiling services to advance hit-to-lead campaigns. The company was founded in 2002. SB Drug Discovery was acquired by Sygnature Discovery Ltd. on January 17, 2023. | Commercial Services |
- Stock Market
- Insiders
- Louisa Jordison